Ferroptosis biomarkers predict tumor mutation burden's impact on prognosis in HER2-positive breast cancer

Table 1 Clinical characteristics of patients in different risk groups in TCGA and METABRIC cohorts, n (%)

	TCGA			Metabric
	High risk group, n = 84	Low risk group, n = 84	P value	High risk group, n = 54	Low risk group, n = 72	P value
Age
< 60	38 (0.45)	40 (0.48)	0.003	34 (0.63)	41 (0.57)	0.606
≥ 60	46 (0.55)	44 (0.52)		20 (0.37)	31 (0.43)
Stage
Ⅰ/Ⅱ	59 (0.70)	58 (0.69)	0.033	40 (0.74)	60 (0.83)	0.101
Ⅲ/Ⅳ	25 (0.30)	26 (0.31)		14 (0.26)	12 (0.17)
Radio therapy
Yes	3 (0.04)	5 (0.06)	0.293	41 (0.76)	49 (0.68)	0.548
No	7 (0.08)	6 (0.07)		13 (0.24)	23 (0.32)
Unknown	74 (0.88)	73 (0.87)		0	0

Table 2 Hub gene differentially expressed between normal and cancer epithelial cells

Gene	P value	Avg_log2FC	Pct.1	Pct.2	P value adjustment
PROM2	9.48E-134	0.115125977	0.096	0.017	1.98E-129
SLC7A11	2.96E-77	-0.101678852	0.016	0.08	6.18E-73
FANCD2	4.01E-27	0.028728862	0.025	0.006	8.38E-23